May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Intravitreal Injections in Patients on Warfarin Anticoagulation
Author Affiliations & Notes
  • O. K. Siddiqi
    Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri
  • P. N. Dayani
    Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri
  • N. M. Holekamp
    Ophthalmology and Visual Sciences, Washington University School of Medicine/ Barnes Retina Institute, St. Louis, Missouri
  • Footnotes
    Commercial Relationships O.K. Siddiqi, None; P.N. Dayani, None; N.M. Holekamp, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 257. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      O. K. Siddiqi, P. N. Dayani, N. M. Holekamp; Intravitreal Injections in Patients on Warfarin Anticoagulation. Invest. Ophthalmol. Vis. Sci. 2007;48(13):257.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate the safety of intravitreal Macugen injections amongst patients on warfarin anticoagulation.

Methods:: A search was conducted for all patients treated with intravitreal Macugen injections for choroidal neovascularization. Inclusion criteria included patients on warfarin anticoagulation, in whom therapy was continued throughout the treatment period.

Results:: Our review identified 31 patients (32 eyes) who underwent a total of 102 intravitreal Macugen injections while maintained on warfarin anticoagulation. The mean and median number of Macugen injections per patient was 3. No intraoperative or immediate postoperative hemorrhagic complications were noted. One patient experienced an acute submacular hemorrhage 35 days after the third Macugen injection. There were no other hemorrhagic events amongst the remaining patients.

Conclusions:: This retrospective chart review found that approximately 10% of patients with exudative AMD will have concomitant medical conditions requiring the use of warfarin anticoagulation. Our data suggests that patients treated with intravitreal Macugen for choroidal neovascularization due to AMD while maintained on warfarin therapy may safely undergo intravitreal injections without cessation of anticoagulation.

Keywords: age-related macular degeneration • injection • vitreoretinal surgery 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×